Regulation of adenylyl cyclase isozymes on acute and chronic activation of inhibitory receptors

Molecular Pharmacology

Volumn 54, Issue 2, 1998, Pages 419-426

  Nevo, Igal ^a   Avidor Reiss, Tomer ^a   Levy, Rivka ^a   Bayewitch, Michael ^a   Heldman, Eli ^b   Vogel, Zvi ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; CYCLIC AMP; DOPAMINE 2 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MU OPIATE RECEPTOR; MUSCARINIC RECEPTOR;

ARTICLE; CELL STRAIN COS1; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; PRIORITY JOURNAL; RECEPTOR BINDING; SENSITIZATION; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

EID: 0031848833     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.2.419     Document Type: Article

References (40)

1. s is enhanced in neuroblastoma X glioma (NG108-15) hybrid cells chronically exposed to an opioid. Mol Pharmacol 43:556-563.
2. Avidor-Reiss T, Bayewitch M, Levy R, Matus-Leibovitch N, Nevo I, and Vogel Z (1995a) Adenylylcyclase supersensitization in μ-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. J Biol Chem 270: 29732-29738.
3. βγ. J Biol Chem 271:21309-21315.
4. Avidor-Reiss T, Nevo I, Saya D, Bayewitch M, and Vogel Z (1997) Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J Biol Chem 272:5040-5047.
5. Avidor-Reiss T, Zippel R, Levy R, Saya D, Ezra V, Barg J, Matus-Leibovitch N, and Vogel Z (1995b) κ-Opioid receptor-transfected cell lines: modulation of adenylyl cyclase activity following acute and chronic opioid treatments. FEBS Lett 361:70-74.
6. Bayewitch ML, Avidor-Reiss T, Levy R, Pfeuffer T, Nevo I, Simonds WF, and Vogel Z (1998) Differential modulation of adenylyl cyclases I and II by various Gβ subunits. J Biol Chem 273:2273-2276.
7. Birnbaumer L, Abramowitz J, and Brown AM (1990) Receptor-effector coupling by G proteins. Biochem Biophys Acta 1031:163-224.
8. Cooper DMF, Mons N, and Karpen JW (1995) Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature (Lond) 374:421-424.
9. Ebadi M, Pfeiffer RF, and Murrin LC (1990) Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol 21:367-386.
10. Gimenez-Roldan S, Tolosa E, Burguera JA, Chacon J, Liano H, and Forcadell F (1997) Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 20:67-76.
11. Glatt CE and Snyder SH (1993) Cloning and expression of an adenylyl cyclase localized to the corpus striatum. Nature (Lond) 361:536-538.
12. Groppetti A, Flauto C, Parati E, Vescovi A, Rusconi L, and Parenti M (1986) Dopamine receptor changes in response to prolonged treatment with L-DOPA. J Neural Transm Suppl 22:33-45.
13. Gulati K (1995) Differential effects of intrahypothalamic administration of opioids on food intake in naive and tolerant rats. Pharmacol Biochem Behav 52:689-694.
14. 9-tetrahydrocannabinol on adenylate cyclase activation in heart. J Pharmacol Exp Ther 252:1075-1082.
15. 2-adrenergic receptor-mediated sensitization of forskolin-stimulated cyclic AMP production in HT29 cells. J Biol Chem 263:14236-14244.
16. Koob GF (1996) Hedonic valence, dopamine and motivation. Mol Psychiatry 1:186-189.
17. Lieberman AN and Goldstein M (1985) Bromocriptine in Parkinson disease. Pharmacol Rev 37:217-227.
18. Lim K and Chae CB (1989) A simple assay for DNA transfection by incubation of the cells in culture dishes with substrates for beta-galactosidase. Biotechniques 7:576-579.
19. Maloteaux JM and Hermans E (1994) Agonist-induced muscarinic cholinergic receptor internalization, recycling and degradation in cultured neuronal cells. Biochem Pharmacol 47:77-88.
20. Maneuf YP, and Brotchie JM (1997) Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398.
21. McDermott AM and Sharp GWG (1995) Noradrenaline induces supersensitivity of adenylyl cyclase in NG108-15 and HT29-18 cells but not in the β-cell RINm5F. Cell Signal 7:277-285.
22. oα subunits. J Biol Chem 270:16070-16074.
23. 2+-inhibitable adenylate cyclase in dopaminergically innervated rat brain regions. Mol Brain Res 22:236-244.
24. Mons N and Cooper DMF (1995) Adenylate cyclases: critical foci in neuronal signaling. Trends Neurosci 18:536-542.
25. Nestler EJ, Hope BT, and Widnell KL (1993) Drug addiction: a model for the molecular basis of neural plasticity. Neuron 11:995-1006.
26. Olianas MC and Onali P (1995) Participation of delta opioid receptor subtypes in the stimulation of adenylyl cyclase activity in rat olfactory bulb. J Pharmacol Exp Ther 275:1560-1567.
27. Olianas MC and Onali P (1996) Characterization of the G protein involved in the muscarinic stimulation of adenylyl cyclase of rat olfactory bulb. Mol Pharmacol 49:22-29.
28. Olmsted TR (1988) Neuroleptic malignant syndrome: guidelines for treatment and reinstitution of neuroleptics. South Med J 81:888-891.
29. 1 adenosine receptor-adenylate cyclase system in rat adipocytes. J Biol Chem 262: 841-847.
30. Premont RT (1994) Identification of adenylyl cyclases by amplification using degenerate primers. Methods Enzymol 238:116-127.
31. Puttfarcken PS and Cox BM (1989) Morphine-induced desensitization and down-regulation at μ-receptors in 7315c pituitary tumor cells. Life Sci 45:1937-1942.
32. 2 agonists on brain stimulation reward. Brain Res 651:283-292.
33. Sharma SK, Klee WA, and Nirenberg M (1975) Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72:3092-3096.
34. Sharma SK, Klee WA, and Nirenberg M (1977) Opiate-dependent modulation of adenylate cyclase. Proc Natl Acad Sci USA 74:3365-3369.
35. Sunahara RK, Dessauer CW, and Gilman AG (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36:461-480.
36. Thomas JM and Hoffman BB (1987) Adenylate cyclase supersensitivity: a general means of cellular adaptation to inhibitory agonists? Trends Pharmacol Sci 8:308-311.
37. Thomas JM and Hoffman BB (1992) Adaptive increase in adenylyl cyclase activity in NG108-15 and S49 cells induced by chronic treatment with inhibitory drugs is not due to a decrease in cyclic AMP concentrations. Cell Signal 4:417-428.
38. Thomas JM and Hoffman BB (1996) Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: role of βγ subunits in transducing enhanced activity of the type VI isoform. Mol Pharmacol 49:907-914.
39. 2 agonists injected peripherally or into nucleus accumbens. Psychopharmacology (Berl) 103:271-276.
40. Zimmermann G and Taussig R (1996) Protein kinase C alters the responsiveness of adenylyl cyclases to G protein alpha and beta-gamma subunits. J Biol Chem 271:27161-27166.